Advances in genomic science have led to the development of targeted therapies for rare and genetic disorders, which currently have high unmet need and smaller patient populations. Despite these developments, a number of challenges remain around commercial planning and bringing these drugs to market, specifically drug distribution channels, patient support programs and molecular testing. Healthcare companies must gain greater disease and market understanding to drive brand success.
Custom Data Solutions for Genetic Disorders
Kantar Health provides customized solutions based on its proprietary, industry-leading information sources and deep clinical, commercial and brand expertise. We help you uncover the trends that address business decisions throughout the product lifecycle.
- Epidemiology and market sizing
- Commercial planning strategies for niche products
- Market research
- Pricing and reimbursement guidance
- Evidence-based forecasting
Global Trends for Cystic Fibrosis, Hemophilia, Lupus and Macular Degeneration
Kantar Health’s proprietary information sources, including National Health and Wellness Survey and Epi Database®, allow you to develop a deeper perspective into the patient experience for rare and genetic disorders.
- Cystic Fibrosis
- Idiopathic Thrombocytopenic Purpura
- Macular Degeneration
Other resources include CancerMPact®, Forecast Architect®, KeyMD® and PainMPact™.